Mural Health Partners with Clinflash to Enhance Patient Payments in Clinical Trials
US-based Mural Health has announced a strategic partnership with China-based Clinflash, both companies specializing in...
Hanx Biopharmaceuticals’ HX009 Receives US IND Approval for Lymphoma Treatment
Wuhan-based firm Hanx Biopharmaceuticals Inc. has announced the receipt of an Investigational New Drug (IND)...
Clover Biopharmaceuticals Partners with Kyuan Trade for Commercial Launch of AdimFlu-S (QIS) in China
China-based Clover Biopharmaceuticals Ltd (Clover; HKG: 2197) has announced the establishment of a commercial partnership...
Minghui Pharmaceutical Initiates First-in-Human Trial for IGF-1R Antibody Fusion Protein MHB018A
China-based Minghui Pharmaceutical Inc. has announced the commencement of a first-in-human Phase Ia trial for...
Shanghai Ark Biopharmaceutical Partners with WuXi STA for Commercial Supply of Ziresovir
China’s Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) has entered into a partnership with WuXi STA,...
China’s NMPA and NHC Tighten Regulations on Tramadol Compound Preparations
The National Medical Products Administration (NMPA) and National Health Commission (NHC) have released a notification...
Sino Biopharmaceutical’s TQ-B3525 Files for Market Approval with CDE
Sino Biopharmaceutical Ltd (HKG: 1177) has announced a market approval filing for its Category 1...
MabPharm’s CMAB007 Receives NMPA Approval for IgE-Mediated Asthma Treatment
Taizhou-based monoclonal antibody (mAb) biosimliars specialist MabPharm Ltd (HKG: 2181) has announced that it has...
Alibaba Health Reports 30.1% Revenue Growth in 2022 Financial Report
China-based Alibaba Health Information Technology Ltd (HKG: 0241) has released its financial report for the...
Enhertu, HER2-Targeted ADC, Officially Launched in China for Breast Cancer Treatment
Enhertu (trastuzumab deruxtecan), a HER2-targeted antibody-drug conjugate (ADC) co-developed by AstraZeneca (AZ, NASDAQ: AZN) and...
BeiGene’s Tislelizumab Approved in China for First-Line Esophageal Squamous Cell Carcinoma
BeiGene (NASDAQ: BGNE) has announced that its programmed death-1 (PD-1) inhibitor, tislelizumab, has been approved...
Bayer’s Copanlisib (Aliqopa) Approved by NMPA for Recurrent Follicular Lymphoma
The National Medical Products Administration (NMPA) has indicated on its website that Bayer’s (ETR: BAYN)...
Azenta Life Sciences and Vazyme Biotech Form Global Partnership for Comprehensive Services
Azenta Life Sciences (NASDAQ: AZTA) has entered into a global partnership with China-based Vazyme Biotech...
3SBio Inc. Initiates Phase III Clinical Study for Thrombopoietin in Chronic Liver Disease Patients
China-based 3SBio Inc. (HKG: 1530) has announced the enrollment of the first patient in a...
Shanghai Junshi Biosciences’ Tuoyi Combo for Triple Negative Breast Cancer Accepted for Review
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced that the regulatory authorities...
Oculis’ OCS-01 Achieves Primary Efficacy Endpoint in Phase III DIAMOND Trial for DME
US-based Oculis Holding AG (NASDAQ: OCS) has announced positive top-line results from Stage 1 of...
Nona Biosciences and ModeX Therapeutics Partner to Develop Polyspecific Antibodies
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), which operates across the...
NHSA Proposes Draft to Enhance Basic Medical Insurance Payment Management for Consumables
The National Healthcare Security Administration (NHSA) has issued a Notice seeking public feedback on draft...
SinoMab BioScience’s SM17 IND Accepted by NMPA for Potential Global First-in-Class Monoclonal Antibody
Hong Kong-based biotech SinoMab BioScience Ltd (HKG: 3681) has announced that the National Medical Products...
China Aims to Establish Basic Elderly Care System by 2025, Outlines Comprehensive Plan
The General Office of the CPC Central Committee and General Office of the State Council...